Key facts
- Mandolin’s last known valuation is $161.0M (Jun 2025).
- It has raised $40.0M; the latest was Early Stage VC ($40.0M) in Jun 2025.
- Notable investors include SV Angel, Greylock, Guillermo Rauch, SignalFire, Maverick Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Mandolin
- ·The full record, as it builds
Funding rounds
No funding rounds for Mandolin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mandolin
Developer of automated back-office tools intended for managing specialty drug administration processes. The company's platform features AI-driven workflows that handle intake and onboarding by interpreting referral forms and clinical notes, verify benefits through payer portal navigation and calls, estimate patient out-of-pocket costs with real-time data integration, review medical policies for prior authorization submissions, and automate claims status tracking and appeals, enabling infusion centers to accelerate authorizations, reduce denials, and increase revenue without additional staffing while maintaining full compliance and transparency.
- Sector
- Information Technology
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 21
- Website
- mandolin.com/
- Ownership
- Privately Held (backing)
Mandolin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mandolin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mandolin in its N-PORT filings yet. We sweep new filings monthly.